

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1621
Policy Title	Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic <i>Pseudomonas</i> lung infection in cystic fibrosis (Adults)
Accountable Commissioner	Kathy Blacker
Clinical Reference Group	A01 Specialised Respiratory CRG
Which stakeholders were contacted to be involved in policy development?	Cystic Fibrosis Trust – two members of the Policy Working Group.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Royal College of Physicians and British Thoracic Society. Both have affiliate membership of the CRG so have been aware of the progress of the policy proposition.
Which stakeholders have actually been involved?	As above. Manufacturer has been encouraged to register as CRG stakeholder.
Explain reason if there is any difference from previous	

question	
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	None
How have stakeholders been involved? What engagement methods have been used?	Through Policy Working Group. All registered stakeholders of the A01 Specialised Respiratory CRG were contacted by email and asked to give feedback on the policy.
What has happened or changed as a result of their input?	Change of title to emphasis adults only. Some amendments to wording and factual corrections to some references have been made. (see appendix1 for detail).
How are stakeholders being kept informed of progress with policy development as a result of their input?	Will be contacted again when policy goes out to consultation.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	Four week public consultation – all stakeholders who responded answered ‘yes’ to question suggesting consultation of up to six weeks.